Journal ArticleOPEN ACCESS

A moving target: Inactivating btk mutations as drivers of follicular lymphoma

Clinical Cancer Research (2021) 27(8) 2123-2125
DOI: 10.1158/1078-0432.CCR-21-0140
2Citations
Citations of this article
9Readers
Mendeley users who have this article in their library.

Abstract

Drugs that target Bruton tyrosine kinase (BTK) have been highly successful and changed the landscape of therapies in B-cell lymphomas. However, their lower rates of effectiveness in follicular lymphoma are unexplained. Recent work describes inactivating BTK mutations that show that at least some follicular lymphomas do not require BTK.

Cite

CITATION STYLE

APA

Afaghani, J., & Taylor, J. (2021). A moving target: Inactivating btk mutations as drivers of follicular lymphoma. Clinical Cancer Research, 27(8), 2123–2125. https://doi.org/10.1158/1078-0432.CCR-21-0140

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free